Accuray Overview

  • Year Founded
  • 1990

Year Founded

  • Status
  • Public

  • Employees
  • 987

Employees

  • Stock Symbol
  • ARAY

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.52
  • (As of Tuesday Closing)

Accuray General Information

Description

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Contact Information

Website
www.accuray.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1240 Deming Way
  • Madison, WI 53717-1954
  • United States
+1 (608)
Primary Industry
Other Devices and Supplies
Other Industries
Other Healthcare Technology Systems
Stock Exchange
NAS
Vertical(s)
Manufacturing, Robotics and Drones, TMT, Life Sciences, Oncology
Corporate Office
  • 1240 Deming Way
  • Madison, WI 53717-1954
  • United States
+1 (608)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Accuray Stock Performance

As of 22-Apr-2025, Accuray’s stock price is $1.52. Its current market cap is $156M with 103M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.52 $1.45 $1.40 - $2.95 $156M 103M 649K -$0.04

Accuray Financials Summary

As of 31-Dec-2024, Accuray has a trailing 12-month revenue of $453M.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023 FY 2022 30-Jun-2022
EV 348,702 327,164 486,522 285,580
Revenue 453,140 446,551 447,605 429,909
EBITDA 14,985 5,709 8,371 11,640
Net Income (4,372) (15,545) (9,280) (5,347)
Total Assets 478,382 468,627 479,214 472,849
Total Debt 213,490 210,747 205,036 199,490
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Accuray Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Accuray‘s full profile, request access.

Request a free trial

Accuray Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatmen
Other Devices and Supplies
Madison, WI
987 As of 2024

Paris, France
 

San Carlos, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Accuray Competitors (15)

One of Accuray’s 15 competitors is TISSIUM, a Venture Capital-Backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TISSIUM Venture Capital-Backed Paris, France
ZAP Surgical Venture Capital-Backed San Carlos, CA
eCential Robotics Venture Capital-Backed Gieres, France
CivaTech Oncology Venture Capital-Backed Durham, NC
Mevion Medical Systems Private Equity-Backed Littleton, MA
You’re viewing 5 of 15 competitors. Get the full list »

Accuray Patents

  • 693

    Total Documents Applications and Grants

  • Total Patents Families

  • 506

    Granted

  • 40

    Pending

  • Expiring in next 12 mo

Accuray Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024156622-A Fundamental of semi-conductor-based photon counting detector Pending 24-Apr-2023
US-20240350833-A1 Fundamentals of semi-conductor-based photon counting detectors Pending 24-Apr-2023
EP-4454702-A1 Fundamentals of semi-conductor-based photon counting detectors Pending 24-Apr-2023
US-11679281-B1 Scalable slim radiotherapy treatment delivery system topology Active 01-Jun-2022
US-20230390588-A1 Scalable slim radiotherapy treatment delivery system topology Pending 01-Jun-2022 A61N5/1081
To view Accuray’s complete patent history, request access »

Accuray Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Accuray Investments & Acquisitions (4)

Accuray’s most recent deal was a Joint Venture with CNNC Accuray (Tianjin) Medical Technology. The deal was made on 28-Jan-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CNNC Accuray (Tianjin) Medical Technology 28-Jan-2019 Joint Venture Therapeutic Devices
Morphormics 16-Jul-2012 Merger/Acquisition Other Healthcare Technology Systems
Compact Particle Acceleration 16-May-2012 Early Stage VC Therapeutic Devices
TomoTherapy 13-Jun-2011 Merger/Acquisition Therapeutic Devices
To view Accuray’s complete investments and acquisitions history, request access »

Accuray ESG

Risk Overview

Risk Rating

Updated March, 22, 2024

31.65 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Healthcare

Industry

of 587

Rank

Percentile

Medical Devices

Subindustry

of 198

Rank

Percentile

To view Accuray’s complete esg history, request access »

Accuray Exits (1)

Accuray’s most recent exit was on 16-May-2012 from Compact Particle Acceleration. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Compact Particle Acceleration 16-May-2012 Completed
  • 4 buyers
To view Accuray’s complete exits history, request access »

Accuray FAQs

  • When was Accuray founded?

    Accuray was founded in 1990.

  • Where is Accuray headquartered?

    Accuray is headquartered in Madison, WI.

  • What is the size of Accuray?

    Accuray has 987 total employees.

  • What industry is Accuray in?

    Accuray’s primary industry is Other Devices and Supplies.

  • Is Accuray a private or public company?

    Accuray is a Public company.

  • What is Accuray’s stock symbol?

    The ticker symbol for Accuray is ARAY.

  • What is the current stock price of Accuray?

    As of 22-Apr-2025 the stock price of Accuray is $1.52.

  • What is the current market cap of Accuray?

    The current market capitalization of Accuray is $156M.

  • What is Accuray’s current revenue?

    The trailing twelve month revenue for Accuray is $453M.

  • Who are Accuray’s competitors?

    TISSIUM, ZAP Surgical, eCential Robotics, CivaTech Oncology, and Mevion Medical Systems are some of the 15 competitors of Accuray.

  • What is Accuray’s annual earnings per share (EPS)?

    Accuray’s EPS for 12 months was -$0.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »